E
EUSA Pharma
Pharmaceutical company developing and licensing late-stage oncology, pain control, and critical care products
About EUSA Pharma
EUSA Pharma is a dynamic, global specialty pharmaceutical company focused on developing and commercializing innovative medicines for oncology and rare diseases. The company serves patients worldwide, aiming to make a meaningful difference in their lives by providing access to life-changing treatments. EUSA Pharma operates in the pharmaceutical market, targeting both healthcare professionals and patients who require specialized therapies. The business model revolves around research and development, clinical trials, regulatory approvals, and the commercialization of its products. Revenue is generated through the sale of its pharmaceutical products, which are distributed globally. The company is committed to expanding its product portfolio and reaching more patients in need.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2005
- Headquarters
- Hemel Hempstead, United Kingdom
- Employees
- 95
- Open positions
- None listed
- Dealroom signal
- 66.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Critical medical care, Disease, Biotech and Pharma, Hard Tech, Became Thoroughbred as Subsidiary, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 1 company, latest May 2008
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2012 | $680M | — | Jazz Pharmaceuticals | — |
| FundingOther financing | May 2009 | $0 | — | Advent Venture Partners · SV Health Investors | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for EUSA Pharma is 550 monthly website visits, down 40.2% over the last three months. EUSA Pharma's team declined 13.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- PIProQuest Investments
OrbiMed- BABristol Capital Advisors
- HLHIGHBRIDGE CAPITAL MANAGEMENT (UK), LTD.
Perceptive Advisors- ICIroquois Capital
Other known investors3 additional known investors
Advent Venture Partners
Jazz Pharmaceuticals
SV Health Investors
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about EUSA Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EUSA Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.